Evaluation of Fractionation Schemes in Breast Cancer Radiotherapy and Dosimetric Study of the Main Organs at Risk
DOI:
https://doi.org/10.15392/bjrs.v10i1.1746Keywords:
External radiotherapy, breast cancer, fractionation, tolerance criteria, organs at risk, radiation protectionAbstract
The purpose of this work was to evaluate the impact of different breast cancer radiotherapy regimens on the acceptance of the tolerance criteria of the main organs at risk, the heart, and the ipsilateral lung.
In this context, the dosimetric treatment plans of 20 breast cancer patients treated at the Radiotherapy Service of Braga Hospital were analyzed. The treatment planning system was the XiO (Elekta) and the dosimetric treatment plans were performed using with 3D-CRT technique (three-dimensional conformal radiation therapy) and the pencil beam algorithm for photon dose calculation.
Two approaches to estimate the equivalence of different radiotherapy schedules have been proposed, the equivalent dose at 2Gy per fraction model and the biologically effective dose model. These models showed that the conventional radiotherapy course to 50Gy in 25 daily fractions is clinically equivalent to the hypofractionation course to 42,56Gy in 16 daily fractions.
Obtained results showed that the tolerance criteria for the organs at risk, the heart and the ipsilateral lung, referring to the hypofractionation course to 42,56Gy in 16 daily fractions, are more restrictive than the tolerance criteria of conventional regimen. This means that if the same setup and the same dose coverage in the planning target-volume are used, the tolerance criteria for the organs at risk of hypofractionation regiment are more difficult to attain.
These results can assist radiation oncologists in the evaluation of radiotherapy prescription doses for breast cancer, in compliance with the principles of radiation protection.
- Views: 250
- PDF Downloads: 235
Downloads
References
CHEN, G.P.; LIU F.; et al. A Planning comparison of 7 irradiation Options Allowed in RTOG 1005 for Early-Stage Breast Cancer. Medical Dosimetry. v. 40, pp. 21-25, 2014. DOI: https://doi.org/10.1016/j.meddos.2014.06.007
APPELT A.L.; VOGELIUS I.R.; et al. Modern Hypofractionation Schedules for Tangential Whole Breast Irradiation Decrease the Fraction Size-corrected Dose to the Heart. Clinical Oncology. v. 25, pp 147-152, 2013. DOI: https://doi.org/10.1016/j.clon.2012.07.012
JONES B.; DALE R.G.; et al. The Role of Biologically Effective Dose (BED) in Clinical Oncology. Clinical Oncology. v. 13, pp 71–81, 2001. DOI: https://doi.org/10.1053/clon.2001.9221
KOULOULIAS, V.E.; ZYGOGIANNI, A.G. Hypofractionated Radiotherapy for Breast Cancer: too fast or too much?. Translational Cancer Research. v. 5, pp 688-693, 2016. DOI: https://doi.org/10.21037/tcr.2016.10.13
WHELAN T.J.; PIGNOL J.P.; et al. Long-term Results of Hypofractionated Radiation Therapy for Breast Cancer. New England Journal of Medicine. v. 362, pp 513–520, 2010. DOI: https://doi.org/10.1056/NEJMoa0906260
TAYLOR, C.; CORREA, C.; et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence from Modern Radiation Doses to the Lungs and Heart and from Previous Randomized Trials. Journal of Clinical Oncology. v. 35, pp 1641-1649, 2017. DOI: https://doi.org/10.1200/JCO.2016.72.0722
SOUMAROVÁ, R.; RUSINOVÁ, L. Cardiotoxicity of Breast Cancer Radiotherapy – Overview of Current Results. Reports of Practical Oncology and Radiotherapy. v. 25, pp 182-186, 2019. DOI: https://doi.org/10.1016/j.rpor.2019.12.008
MOSAIQ brochure (visited 29/07/21) https://www.elekta.com/dam/jcr:d79cff58-91ce-4d4c-b27d-472dc38da371/MOSAIQ-RO-brochure.pdf
SHARON QI, X.; WHITE, J; et al. Is α/β for Breast Cancer Really Low?. Radiotherapy and Oncology. v. 100, pp 282–288, 2011. DOI: https://doi.org/10.1016/j.radonc.2011.01.010
VASSILIS, K.; IOANNIS, G.; et al. A Unique Hypofractionated Radiotherapy Schedule with 51.3Gy in 18 Fractions Three Times per Week for Early Breast Cancer: Outcomes Including Local Control, Acute and Late Skin Toxicity. Breast Cancer. v. 24, pp 263-270, 2017. DOI: https://doi.org/10.1007/s12282-016-0697-0
XiO brochure (visited 29/07/21) https://www.elekta.com/dam/jcr:b3948f4a-0ac8-4317-9b89-41178a44a670/XiO-Comprehensive-RTP-System-product-brochure.pdf
BEATOM, L.; BERGMAN, A.; et al. Cardiac Death after Breast Radiotherapy and the QUANTEC Cardiac Guidelines. Clinical and Translational Radiation Oncology. v. 19, pp 39–45, 2019. DOI: https://doi.org/10.1016/j.ctro.2019.08.001
ZEVERINO, M.; PETERSSON, K.; et al. A Treatment Planning Comparison of Contemporary Photon-based Radiation Techniques for Breast Cancer. Physics and Imaging in Radiation Oncology. v. 7, pp 32–38, 2018. DOI: https://doi.org/10.1016/j.phro.2018.08.002
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard :Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer. Principal Investigator: VICINI, F. NRG Oncology, GRTOG 1005, 2014.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
